



A Team with Experience and Dedication

Vystar Corporation's leadership team of seasoned professionals brings broad-based expertise in sales, marketing, strategic planning, finance, and research and development in medical devices, pharmaceuticals, banking, and consumer markets to the company.

William R. Doyle, Chairman of the Board, President and Chief Executive Officer, was originally part of the Vystar Team as Senior Vice President of Sales and Marketing. His role expanded in November 2005 as he became company President and a member of the Board of Directors. Mr. Doyle assumed the role of Chairman of the Board and CEO in April 2008 when Travis Honeycutt retired. Mr. Doyle will be representing Vystar by delivering a paper in Japan in front of the Japan Rubber Association during the fall of 2009 and has been invited to present at the Smithers-RAPRA Latex 2010 conference in Amsterdam, March 2010. He has co-authored and presented numerous papers for Vystar globally since its inception and has served as section chair at latex conferences previously.

Prior to joining Vystar, Mr. Doyle was Vice President of Marketing, Women's Health for Matria Healthcare, Inc. (now Alere) where he spearheaded the initial branding efforts and held responsibility for sales development, training, public relations, and marketing. He has worked in many aspects of healthcare for over twenty five years encompassing manufacturing, sales, marketing and advertising with such companies as Isolyser Company, Inc., McGaw, Inc., Lederle Laboratories (now Wyeth), and in an advertising capacity for Novartis Ophthalmics. Mr. Doyle is a member of the Board of Directors of the Georgia Chapter of the March of Dimes where he is a past Chairman of the Prematurity Campaign. He holds a Bachelor of Science in Biochemistry from Penn State University and Master of Business Administration from Pepperdine University's Graziadio School of Business and Management.

Jack W. Callicutt, Chief Financial Officer, joined Vystar in April 2010 as Chief Financial Officer. Prior to that, Mr. Callicutt served as Chief Financial Officer of IVOX, Inc., an Atlanta, GA based technology enabled transportation risk management company, from April 2008 through September 2009. Mr. Callicutt served as Vice President and Chief Financial Officer of Tikvah Therapeutics, a privately held biotechnology company in Atlanta, GA, from August 2007 through March 2008. Prior to joining Tikvah, Mr. Callicutt was employed by Corautus Genetics, Inc., a publicly traded biotechnology company based in Atlanta, GA, from August 2003 through June 2007, most recently serving as Senior Vice President – Chief Financial Officer. During his career, Mr. Callicutt has completed several private placements and convertible debt offerings and has made numerous presentations at investor and industry conferences. Mr. Callicutt also negotiated and completed merger and acquisition transactions in addition to being responsible for all financial, risk management and administrative functions. Prior to joining Corautus, Mr. Callicutt spent 14 years with Deloitte, an international public accounting firm, the last six years as an audit senior manager primarily focusing on technology companies. Mr. Callicutt is a Certified Public Accountant and graduated, with honors, from Delta State University with degrees in Accounting and Computer Information Systems. Mr. Callicutt has served on several boards of non-profit organizations.

Sandra G. Parker, Executive Vice President, Business Development and Marketing, is a healthcare industry professional with over 25 years of progressive sales and marketing management experience. She has been an officer of Vystar Corporation since 2008 where she has responsibility for the development and execution of the corporation's marketing strategies including brand development and positioning, identification of new customers and markets, creation of channel strategies and relationships and mid-long term strategic planning.

Her career has spanned the clinical, hospital, trade association, group purchasing, distribution and manufacturing sectors in Fortune ranked and market-leading companies including General Medical Corporation (now McKesson), Teleflex, Safeskin Corporation (now Kimberly-Clark) and Kimberly-Clark Corporation. She most recently served as senior manager for Kimberly-Clark Healthcare where she was the architect for their expansion into surgery center, physician, dental, EMS and other non-hospital markets. Prior to Kimberly-Clark, Ms. Parker held the position of marketing director for Isolyser Company Inc. (now Ecolab), where she spearheaded product development and brand development for a firm specializing in surgical and infection control solutions. Ms. Parker is the recipient of many sales and marketing awards throughout her career including most recently President Club Sales and Outstanding Leadership honors at Kimberly-Clark. She has served on numerous industry committees overseeing the development of national plans addressing public health issues such as avian flu and emergency response. During her tenure as Vice President, the South Florida Hospital Association, Ms. Parker frequently spoke nationally on contemporary healthcare issues including reimbursement, medical credentialing and emergency management. She currently serves in a national leadership role as Chair, Professional Women in Healthcare (PWH), a professional development organization for leading women in healthcare manufacturing and distribution. She is a graduate of Jackson Memorial School of Nursing, Miami, FL.

Matthew P. Clark, Vice President, Technical Sales, has been an executive officer of Vystar since 2004 and has worked in natural rubber latex R&D since 2000. He is responsible for day-to-day Vystar sales operations as well as IP, trademark and product development. A co-patent holder on the process to reduce the allergenicity of natural rubber latex prior to vulcanization, Mr. Clark is a key company contact for latex industry leaders. He is co-author of five technical papers, "Technological and Physical Properties of a New, Low Antigenic Protein Natural Rubber Latex",

"The Business Aspects of Vytex, an Ultra Low Protein Natural Rubber Latex", "Vytex Natural Rubber Latex: A Proposed Industry Standard for the Manufacture of Commercial Natural Rubber Products", "Vytex Natural Rubber Latex: An Innovative Source Material for Natural Rubber Products Prior to Vystar and "Vytex™: A Low Protein Natural Rubber Source for the Production of Reduced Protein Latex Products". Mr. Clark is an active participating member in ASTM D.11 on Rubber. Also, he is a Toastmaster international member.

Prior to his involvement in natural rubber latex, he had supervisory roles at Isolyser from 1995 to 2000 and Globe Ticket and Label Company thereafter. He is a graduate of Gwinnett Technical Institute.

Dawn E. Ely, JD, General Counsel, has nearly two decades of in-depth experience in healthcare and technology and in the role of Chief Legal Officer, managing business units while providing corporate legal work, strategic counsel and negotiations, serving on Executive Management teams providing strategic legal and regulatory direction across global business groups in large and small private and public companies. Past experience includes roles as General Counsel (Coloplast Corp), Global Health Care Regulatory Counsel, Chief Privacy Officer, Regional Head of Regulatory & Quality (Agfa & its Regional divisions) and VP Legal & Administrative Affairs of multiple healthcare and technology companies, international and domestic. Ms. Ely is a frequent speaker and educator, and was most recently a speaker at the inaugural International Women's Entrepreneurship & Leadership Summit in Istanbul, Turkey, June 2009. She is on the Boards of Zonta International's Buckhead Chapter and the American-Turkish Friendship Council in Atlanta. She was educated at the University of Virginia, B.A. (distinguished honors major) and Mercer University, J.D. and is licensed to practice law in North Carolina and Georgia, U.S.

Ranjit K. Matthan, Ph.D, Polymer Consultant, has been associated with the development of natural rubber and rubber based industries manufacturing in South Asia since the 1970's, having introduced technically specified natural rubber into India during this time. He is an active promoter of natural rubber throughout India and South Asia and has advised leading national and international companies and research bodies including the government of India, the Malaysian Rubber Research and Development Board, Asian Development Bank, Industrial Development Bank of India, Revertex (Malaysia) as well as many private companies engaged in latex production and manufacturing. Dr. Matthan has presented and published over 50 scientific and technical papers on natural rubber and lattices and is an invited speaker at several international conferences including the International Latex Conference held each year in the USA.

He currently serves as a Director for KA Prevulcanised Latex Ltd, Nagercoil, India. He is a member of the Governing Councils for All India Rubber Industries Association, Indian Rubber Manufacturers Research Association, Indian Rubber Institute and Board of Governors and Executive Committee of the Scheffelin Leprosy Research and Training Institute. In 2006, he was awarded the 1005-2006 K.M. Philip Gold Medal and Award for outstanding contributions to the development of the Indian Rubber industry and Human Resource Development through Education and Training in India.

Dr. Matthan holds an undergraduate degree from St. Stephens College, Delhi University, India and he earned his Ph.D in Polymer Chemistry from the National College of Rubber Technology, London, England, where he was the first Ph.D student of Dr. D.C. Blackley whose books and high polymer lattices and emulsion polymerization are the industry standard references.

Catharine Calkins Burke, Ph.D, Technical Consultant, is an accomplished biomedical researcher with extensive academic experience with leading institutions such as Emory University, University of Georgia and Wayne State University. She has co-authored over 35 technical papers and abstracts on a wide range of topics focused on wound healing, cancer biology, periodontal disease, cutaneous biology, and stem cell. Dr. Calkins has received numerous achievement awards throughout her career including Outstanding Graduate Student, Wayne State University School of Graduate Studies and the National Research Service Award (NRSA) in Dermatology. Dr. Calkins holds a Ph.D. degree in Pharmacology from Wayne State University, Detroit, Michigan and Bachelors of Science degree in Chemistry/Biochemistry from San Jose State University, San Jose, California.

Russell D. Culp, Industry Consultant, utilizes his more than 25 years of experience in latex compound development, latex dipping technologies and research and development, to help Vystar's manufacturing clients integrate the proprietary Vytex® Natural Rubber Latex (NRL) technology into production lines. He served as the chairman of the A.S.T.M. D11.40 Subcommittee, which has responsibility for writing and reviewing standards for consumer rubber products for four years (1986-1990). He has been a consultant and held key technical services positions with Alatech Healthcare, LLC; Ansell, Incorporated; Baxter Healthcare; LMR International; and London International Group / Aladan Corporation. Mr. Culp holds a bachelor degree in biology from Troy State University.

Mark C. Swanson, Technical Advisor, is an immunochemist of 30 years working for the Mayo Foundation, Rochester, MN. He graduated in 1978 from St. Cloud State University, St. Cloud, MN with degrees in bio-medical science and chemistry. He founded Quan-Tec-Air, Inc. in 1985. The company is dedicated to the quantification of asthmagenic bio-aerosols using specialized sampling, filtration and immunoassay techniques. The combination of air sampling expertise and de novo immunoassay design and implementation makes him a unique and valuable resource for immuno-aero-biological health hazard assessment. Mr. Swanson is contacted frequently by industry and agencies interested in evaluating workplace bio-aerosols and their remedies.